upadacitinib
abbvie
['select-axis', 'select,axis,2', ' upa ']
select-axis 2 subgroup analysis. upa demonstrated improved efficacy vs pbo at wk 14 across all evaluated subgroups of pts with bdmard-ir as. no new safety signals. et al, abs 0414 #acr22 
Passionately curious rheumatologist, world traveler, wife, mother, sister, daughter, friend, dog lover. Believer in scientific method & evidence based medicine.